What is the role of Helicobacter pylori testing and eradication in the work‑up and treatment of immune thrombocytopenia?

H. Pylori Testing in Immune Thrombocytopenia

Test all adult patients with ITP for active H. pylori infection and eradicate if positive—this approach can achieve platelet recovery in approximately 50% of infected patients and should be pursued before escalating to more aggressive therapies. 1

Diagnostic Approach

Who to Test

• Adults with ITP: Screen all adult patients with newly diagnosed, persistent, or chronic ITP for H. pylori infection 1
• Children with ITP: Routine testing is not recommended in pediatric patients, as evidence shows no benefit over placebo in this population 2

Preferred Testing Methods

Use non-invasive tests for active infection rather than serology:

• Urea breath test (UBT): Sensitivity and specificity >90% for active infection 3, 4
• Stool antigen test: Sensitivity 94%, specificity 92% 5
• Endoscopic biopsy (if endoscopy performed for other indications): Most accurate method using immunohistochemistry 4

Critical testing considerations:

• Stop PPIs for at least 7-14 days before testing (causes false negatives) 3, 6
• Stop antibiotics and bismuth for at least 4 weeks before testing 3
• Never use serology alone for diagnosis—antibodies remain elevated after eradication and cannot distinguish active from past infection 3, 4

Treatment Protocol

When H. Pylori is Detected

Eradicate immediately using standard regimens 1:

First-line therapy (14 days):

• PPI (standard dose twice daily)
• Plus Clarithromycin 500 mg twice daily
• Plus Amoxicillin 1 g twice daily (or metronidazole 500 mg twice daily if penicillin allergic)
• Eradication rates approach 90% in low clarithromycin resistance areas 3

Alternative first-line (in high clarithromycin resistance regions):

• Bismuth-containing quadruple therapy for 10-14 days 6

Second-line therapy (if first-line fails):

• Levofloxacin-based triple therapy for 10 days 5

Confirming Eradication

Test for cure at least 4 weeks after completing therapy using:

• UBT or stool antigen test (not serology) 6
• Ensure patient remains off PPIs, antibiotics, and bismuth during this period

Expected Outcomes

Platelet Response Rates

• Overall response rate: 50.3% in H. pylori-positive patients after successful eradication 2
• Complete response: Patients achieving CR at 2 months typically maintain higher platelet counts long-term 7
• Time to response: Platelet recovery typically occurs within 2-3 months post-eradication 8

Factors Predicting Better Response

• Higher baseline platelet counts (30-80 × 10³/μL range) 8
• Geographic regions with high H. pylori prevalence 2
• Successful eradication (not just treatment attempt) 7

Clinical Algorithm

1. Diagnose ITP → Exclude secondary causes
2. Test for active H. pylori (UBT or stool antigen preferred)
3. If positive → Eradicate using appropriate regimen
4. Confirm eradication at 4+ weeks post-treatment
5. Monitor platelets for 2-6 months
6. If no response by 3 months → Consider standard ITP therapies (corticosteroids, IVIG, TPO-RAs)

Key Advantages of This Approach

• Avoids immunosuppression in responders
• Simple, time-limited treatment (10-14 days)
• Durable responses when successful 7
• Cost-effective compared to chronic ITP therapies
• Addresses underlying pathology rather than just symptoms

Important Caveats

Do not delay urgent ITP treatment for H. pylori testing/eradication in patients with:

• Active bleeding requiring immediate intervention
• Platelet counts <10 × 10³/μL with bleeding risk
• Need for urgent procedures

In these cases, initiate standard ITP therapy (corticosteroids, IVIG) while simultaneously testing and treating H. pylori 1.

Pediatric exception: The evidence does not support routine H. pylori testing in children with ITP, as eradication showed no benefit over placebo in randomized trials 2. The prevalence in affected children mirrors the general pediatric population, suggesting no causal relationship.